As of November 6, 2026, Mural Oncology plc has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 7 filings are on record since August 5, 2025 (Schedule 13G/A, December 16, 2025).
Sell to companies like Mural Oncology plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Trium Capital LLP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Prosight Management, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Trium Capital LLP · Percent: 10.2% · SCHEDULE 13G
- · Holder: Armistice Capital, LLC · Percent: 0% · SCHEDULE 13G/A
Mural Oncology plc has 7 Schedule 13D or 13G filings on record since 2025-08-05. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 |
| Armistice Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Solas Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Trium Capital LLP | 0% | 0 | SCHEDULE 13G/A, 2025-12-16 | 2025-12-11 |
| Prosight Management, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
Holding shares or following this stake? See who's behind Mural Oncology plc and the warning signs.
Free to see. No signup.
Keep reading
More on Mural Oncology plc and the records around it.
Companies that share a holder
- Trium Capital LLP also filed stake reports on 4 other companies: RE/MAX Holdings, Inc. (Oct 2026), Sotherly Hotels Inc. (Apr 2026)
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), ADC Therapeutics SA (Feb 2026), MeiraGTx Holdings plc (Feb 2026)
- Solas Capital Management, LLC also filed stake reports on 5 other companies: FENNEC PHARMACEUTICALS INC. (Aug 2026), MAIA Biotechnology, Inc. (Aug 2026), Modular Medical, Inc. (Aug 2026)
Watch Mural Oncology plc
Get an email when Mural Oncology plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mural Oncology plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mural Oncology plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mural Oncology plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Soleus Capital Master Fund, L.P. | 7.6% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Solas Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2025-09-02 | Trium Capital LLP | 10.2% | SCHEDULE 13G |
| 2025-11-07 | Soleus Capital Master Fund, L.P. | 0% | SCHEDULE 13G/A |
| 2025-11-13 | Prosight Management, LP | 0% | SCHEDULE 13G/A |
| 2025-12-16 | Trium Capital LLP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Mural Oncology plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.